GeoVax enters $1 million revolving loan deal, replaces five board members
Bowery Consulting Group's loan brought three new directors to GeoVax's board as five departing members resigned, with source documents giving differing dates for the agreement.
GeoVax Labs, Inc. announced an unsecured revolving loan agreement with Bowery Consulting Group Inc. The company's press release describes the agreement as a $1,000,000 Revolving Loan Agreement dated October 23, 20261. The Form 8-K filing itself states a different date, saying that on October 25, 2026, GeoVax Labs Inc. entered into a Revolving Loan Agreement with Bowery Consulting Group Inc.1 The exhibit list in the same filing also identifies the Revolving Loan Agreement as dated October 25, 2026 between GeoVax Labs, Inc. and Bowery Consulting Group Inc.1
Under the terms described in the 8-K, the company may request loans from time to time before the maturity date, in an aggregate principal amount outstanding at any one time not exceeding $1,000,000.1 As of the filing date, GeoVax had not borrowed any amounts under the agreement and no principal was outstanding.1 Loans bear interest at 12% per annum, calculated on a 360-day year of twelve 30-day periods, with interest payable at maturity.1 All loans and accrued interest are due on the first anniversary of closing, may be prepaid without penalty, and may be reborrowed, though no new loans may be requested within ten business days of maturity.1
The filing also states the lender is not affiliated with the company.1
As part of the transaction, five directors, Randal Chase, Dean Kollintzas, Nicole Lemerond, Jayne Morgan and John Spencer, Jr., resigned, and the remaining board members appointed three lender-designated individuals, Steven Brown, Tyler O'Brien and Manpreet Uppal, as directors.1 The filing notes the appointment of these three nominees was a condition of the lender's obligations under the loan agreement.1
GeoVax also disclosed terms tied to future financing. The company agreed to use reasonable best efforts to complete a public equity offering raising at least $5,000,000, and the agreement contemplates additional offerings reaching $10,000,000 in total gross proceeds.1
Fact check notes
- Imprecise
GeoVax enters $1 million revolving loan deal, replaces five board members
The $1M loan and five director resignations are accurate, but 'replaces five board members' overstates the facts: only three new directors were appointed (not five), and the board shrank from presumably seven to five total members. This is an imprecise characterization of a 5-resign/3-appoint swap. - Checker's noteHeadline says GeoVax 'replaces five board members,' but the filing shows only three new directors were appointed to replace the five who resigned, with the board shrinking from a presumed seven to five total members—this is an imprecise characterization, not a one-for-one replacement of five members.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.